No CrossRef data available.
Article contents
A Controlled Study of the Effectiveness of Nialamide (“Niamid”) in Schizophrenia
Published online by Cambridge University Press: 08 February 2018
Extract
Nialamide is claimed to inhibit the activity of the enzyme monoamine oxidase which is known to be responsible for the breakdown by catalytic oxidation of various amines, e.g. serotonin and norepinephrine. It has been suggested that depression may be associated with inadequate levels of serotonin and/or norepinephrine and that the administration of a monoamine oxidase inhibitor should rationally help to relieve depression. No serious side-effects have been reported in the available literature except that agitated patients might become somewhat more agitated and overactive.
- Type
- Original Articles
- Information
- Copyright
- Copyright © Royal College of Psychiatrists, 1961
eLetters
No eLetters have been published for this article.